Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 11/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24423445 | 0.87 | GAA (0.40) | FFAR4KDM5ATBK1MC4RKCNH2 | |
| SCHEMBL29584681 | 0.87 | GAA (0.40) | FFAR4KDM5ATBK1MC4RKCNH2 | |
| SCHEMBL29585699 | 0.86 | ALDH1A1 (0.41) | FFAR4KDM5ATBK1 | |
| SCHEMBL29585218 | 0.86 | NPC1 (0.40) | TBK1TACR3 | |
| SCHEMBL24423278 | 0.86 | FFAR4 (0.38) | FFAR4TBK1 | |
| SCHEMBL24423009 | 0.85 | FFAR4 (0.39) | FFAR4KDM5ATBK1MC4RKCNH2 | |
| SCHEMBL24423513 | 0.85 | FFAR4 (0.39) | FFAR4KDM5ATBK1MC4RKCNH2 | |
| SCHEMBL29585378 | 0.83 | NPC1 (0.48) | — | |
| SCHEMBL24423905 | 0.83 | NPC1 (0.48) | — | |
| SCHEMBL29583319 | 0.80 | KDM5A (0.40) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | FFAR4 25/4885KDM5A 4027/4885TBK1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.